Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 7:31 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1129–1152 of 7,052 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo- matched Clear all

Conditions: Acute Coronary Syndromes
Interventions: Apixaban, vitamin K antagonist, Acetylsalicylic acid, Acetylsalicylic acid placebo; Drug · Other
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 95 Years
Enrollment: 4,614 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 143
States / cities: Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 125 more

Conditions: Cystic Fibrosis
Interventions: FTI, AZLI, Placebo, AZLI; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 36
States / cities: Anchorage, Alaska • Phoenix, Arizona • Tucson, Arizona + 32 more

Conditions: Alcohol Use Disorder
Interventions: Nimodipine, Placebo; Drug
Lead sponsor: Yale University; Other
Eligibility: 21 Years to 50 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Nasal Polyposis
Interventions: Benralizumab 30 mg SC + Mometasone Furoate, Matching placebo SC + Mometasone Furoate; Biological
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 413 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 48
States / cities: Birmingham, Alabama • Fresno, California • Huntington Beach, California + 37 more

Conditions: HIV-1-infection
Interventions: ISL/LEN, B/F/TAF, PTM B/F/TAF, PTM ISL/LEN; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 609 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 60
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 50 more

Conditions: ADHD
Interventions: AMPH ER Tab 5, 10, 15 and 20 mg, AMPH ER Tab Matching Placebo 5, 10, 15 and 20 mg; Drug
Lead sponsor: Tris Pharma, Inc.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 130 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 3
States / cities: Bradenton, Florida • Maitland, Florida • Las Vegas, Nevada

Conditions: Eosinophilic Esophagitis (EoE)
Interventions: Oral Budesonide Suspension (OBS), Placebo; Drug
Lead sponsor: Shire; Industry
Eligibility: 11 Years to 55 Years
Enrollment: 318 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 77
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 64 more

Conditions: Depressive Disorder, Major
Interventions: Rapastinel, Placebo; Drug
Lead sponsor: Naurex, Inc, an affiliate of Allergan plc; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 429 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 40
States / cities: Dothan, Alabama • Phoenix, Arizona • Imperial, California + 34 more

Conditions: Prostate Cancer
Interventions: ZD4054, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 896 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 19
States / cities: Tucson, Arizona • Greenbrae, California • Los Angeles, California + 16 more

Conditions: Healthy Volunteers
Interventions: TAK-788, Placebo; Drug
Lead sponsor: Millennium Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 69 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Plaque Psoriasis
Interventions: PF-06826647 tablet, PF-06826647 oral suspension, Placebo oral solution/suspension, Placebo tablet; Drug · Other
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 109 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Anaheim, California

Conditions: Cystic Fibrosis
Interventions: VX-661 Plus Ivacaftor Combination, Ivacaftor, VX-661 Plus Ivacaftor Combination Placebo, Ivacaftor placebo; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 12 Years and older
Enrollment: 510 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 27
States / cities: Little Rock, Arkansas • Long Beach, California • Denver, Colorado + 24 more

Conditions: End Stage Kidney Disease
Interventions: CSL300, Placebo; Drug
Lead sponsor: CSL Behring; Industry
Eligibility: 18 Years and older
Enrollment: 3,110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 166
States / cities: Decatur, Alabama • Huntsville, Alabama • Montgomery, Alabama + 121 more

Conditions: Catecholaminergic Polymorphic Ventricular Tachycardia Type 1
Interventions: S48168 (ARM210), Matching Placebo; Drug
Lead sponsor: RyCarma Therapeutics, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Renal Insufficiency, Chronic
Interventions: Balcinrenone/dapagliflozin, Dapagliflozin, Placebo matching Dapagliflozin, Placebo matching balcinrenone/dapagliflozin; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 2,800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 68
States / cities: Huntsville, Alabama • Surprise, Arizona • Tempe, Arizona + 63 more

Conditions: Duchenne Muscular Dystrophy, Becker Muscular Dystrophy
Interventions: Ataluren, Placebo; Drug
Lead sponsor: PTC Therapeutics; Industry
Eligibility: 5 Years and older · Male only
Enrollment: 174 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 15
States / cities: Sacramento, California • Aurora, Colorado • Pensacola, Florida + 12 more

Conditions: Opioid Use Disorder
Interventions: Palmitoylethanolamide, Placebo; Drug · Other
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 65 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Bunion, Pain
Interventions: Tapentadol, Matching Placebo; Drug
Lead sponsor: Grünenthal GmbH; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 177 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Smoking
Interventions: Cycloserine, Placebo; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 55 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: West Haven, Connecticut

Conditions: Alcohol Use Disorder, Alcohol Misuse
Interventions: Placebo, Apremilast; Drug
Lead sponsor: National Institute on Alcohol Abuse and Alcoholism (NIAAA); NIH
Eligibility: 21 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 3
States / cities: Los Angeles, California • Aurora, Colorado • Charlottesville, Virginia

Conditions: Twin; Complicating Pregnancy, Postpartum Hemorrhage
Interventions: Methylergonovine, Placebo; Drug
Lead sponsor: Columbia University; Other
Eligibility: Up to 65 Years · Female only
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: New York, New York

Conditions: Knee Arthritis, Knee Osteoarthritis, Knee Pain Chronic, Knee Discomfort, Rheumatoid Arthritis, Knee Pain Swelling
Interventions: Gold Factor (Gold Nanoparticles, AuNPs), Placebo; Dietary Supplement
Lead sponsor: 4Life Research, LLC; Industry
Eligibility: 18 Years to 87 Years
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Rheumatoid Arthritis
Interventions: MRC375, Matching Placebo, MRC375 150mg; Drug
Lead sponsor: Molecular Research Center, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 19
States / cities: Mobile, Alabama • Long Beach, California • Los Alamitos, California + 16 more

Conditions: Opioid-induced Constipation
Interventions: Naldemedine, Placebo; Drug
Lead sponsor: Shionogi; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 1,246 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 99
States / cities: Birmingham, Alabama • Mobile, Alabama • Chandler, Arizona + 96 more

Search by objective public record fields.

A Study of Apixaban in Patients With Atrial Fibrillation, Not Caused by a Heart Valve Problem, Who Are at Risk for Thrombosis (Blood Clots) Due to Having Had a Recent Coronary Event, Such as a Heart Attack or a Procedure to Open the Vessels of the Heart

Study Evaluating Fosfomycin/Tobramycin for Inhalation in Cystic Fibrosis Patients With Pseudomonas Aeruginosa Lung Infection

Effects of Nimodipine on Alcohol Drinking

Efficacy and Safety Study of Benralizumab for Patients With Severe Nasal Polyposis

Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People With HIV-1

Amphetamine Extended-Release Tablets in the Treatment of Adults With ADHD

A Study in Adolescents and Adults With Eosinophilic Esophagitis (EoE) Measuring Histologic Response and Determine if Reduction in Dysphagia is Achieved

A Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder (RAP-MD-03)

A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) in Hormone Resistant Prostate Cancer With Bone Metastases

A Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of TAK-788 Followed by Evaluation of the Effects of a Low-Fat Meal on TAK-788 PK and Evaluation of Relative Bioavailability of TAK-788 Capsules in Healthy Participants

A First in Human Study to Evaluate Safety, Tolerability, and Pharmacology of PF-06826647 in Healthy Subjects and Subjects With Plaque Psoriasis

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor

Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)

Treatment of an Inherited Ventricular Arrhythmia

A Phase III Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With CKD Stage 3b and 4 (BalanceD-CKD)

Phase 2B Study of PTC124 (Ataluren) in Duchenne/Becker Muscular Dystrophy (DMD/BMD)

Endocannabinoids, Stress, Craving And Pain Effects Study

Intravenous Tapentadol in Post-Bunionectomy Pain

The Effect of Cycloserine on Smoking Behavior in Nicotine Dependent Smokers

Human Laboratory Study of Apremilast for Alcohol Use Disorder

Prophylactic Methylergonovine for Twin Cesarean

Gold Factor on Knee Joint Health and Function

A Study of Two Doses of MRC375 in Moderate to Severe Rheumatoid Arthritis Patients

Long Term Safety of Naldemedine